A Phase 2 interventional study of Upadacitinib and Placebo in Non-Segmental Vitiligo, sponsored by AbbVie. Completed at 35 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Vitiligo with a site in United States — 14 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.
Among the 80 studies in Vitiligo with a site in United States, this one is the 16th largest by enrollment of the 68 interventional ones that give a count, is one of 9 that started in 2021, is one of 31 in phase 2, and was the 48th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →14 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Poland
Ages 18–65
CorEvitas · Sites in United States
Ages 12+ · Healthy volunteers
Eli Lilly and Company · Sites in United States, Belgium, Canada and 2 more countries
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 9 more countries
Ages 18–99
Elixiron Immunotherapeutics (Hong Kong) Ltd. · Sites in United States, Taiwan
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 14 · Phase 4 1
First in 1995; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 185 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 37 across the 68 interventional studies, 1,750 across the 12 observational. Of the 50 that completed or were terminated, 25 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 80 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 4 studies filed under Vitiligo — fewer than ten, so there is no comparison to draw.
8 of the studies in Vitiligo with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06163326Phase 3PfizerA 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | 2027-03-31 |
| NCT06072183Phase 3PfizerA 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 | 2027-07-30 |
| NCT03577327Northwestern UniversityThe Gut and Skin Microbiome in Vitiligo Disease Progression | 2026-12 |
| NCT07223229Elixiron Immunotherapeutics (Hong Kong) Ltd.Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients | 2026-12-31 |
| NCT07108283TakedaA Study of Zasocitinib in Adults With Nonsegmental Vitiligo | 2027-03-26 |
Add all 8 to your calendar (.ics) → With an account.
Among the 80 studies in Vitiligo with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo. Adverse effects and change in disease activity will be assessed.
Upadacitinib is being evaluated for the treatment of non-segmental vitiligo. The study will enroll approximately 160 participants aged 18-65 with non-segmental vitiligo in 5 treatment arms across 35 sites worldwide.
Participants will either receive study drug vs placebo oral tablets once daily (QD) for 24 weeks (Period A). In Period B (up to 52 weeks), participants who received placebo during the first 24 weeks will switch to study drug. Participants who received study drug during the first 24 weeks, will continue to receive study drug.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with all of the following at Screening and Baseline.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received upadacitinib 22 mg administered orally once a day (QD) as tablets for 24 weeks during Period 1. Participants then received upadacitinib 22 mg administered orally once a day (QD) as tablets for 28 weeks during Period 2.
Drug: Upadacitinib
Participants received upadacitinib 11 mg administered orally once a day (QD) as tablets for 24 weeks during Period 1. Participants then received upadacitinib 11 mg administered orally once a day (QD) as tablets for 28 weeks during Period 2.
Drug: Upadacitinib
Participants received upadacitinib 6 mg administered orally once a day (QD) as tablets for 24 weeks during Period 1. Participants then received upadacitinib 6 mg administered orally once a day (QD) as tablets for 28 weeks during Period 2.
Drug: Upadacitinib
Participants received Placebo for upadacitinib administered orally once a day (QD) as tablets for 24 weeks during Period 1. Participants then received upadacitinib 22 mg administered orally once a day (QD) as tablets for 28 weeks during Period 2.
Drug: Upadacitinib · Drug: Placebo
Participants received Placebo for upadacitinib administered orally once a day (QD) as tablets for 24 weeks during Period 1. Participants then received upadacitinib 11 mg administered orally once a day (QD) as tablets for 28 weeks during Period 2.
Drug: Upadacitinib · Drug: Placebo
Oral tablets
Also known as: ABT-494, RINVOQ
Oral tablets
Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3, with higher scores indicating more severe disease. Negative changes from baseline indicate improvement.
Time frame: Baseline, Week 24
Percentage of Participants Achieving F-VASI 75 (≥ 75% Improvement in F-VASI From Baseline) at Week 24
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3, with higher scores indicating more severe disease.
Time frame: Baseline, Week 24
Percentage of Participants Achieving F-VASI 50 (≥ 50% Improvement in F-VASI From Baseline) at Week 24
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3, with higher scores indicating more severe disease.
Time frame: Baseline, Week 24
Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 (≥ 50% Improvement in T-VASI From Baseline) at Week 24
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100, with higher scores indicating more severe disease.
Time frame: Baseline, Week 24
Percent Change From Baseline in T-VASI at Week 24
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100, with higher scores indicating more severe disease. Negative changes from baseline indicate improvement.
Time frame: Baseline, Week 24
Change From Baseline in the Vitiligo Quality-of-Life (VitiQoL) Instrument Total Score at Week 24
The VitiQoL is a validated questionnaire used in clinical trials to assess stigma-related vitiligo impacts. The VitiQoL uses subject-elicited social, affective, and behavior items, asking the subject's appraisal of the vitiligo-related impacts over the last month. Fifteen items are scored on a 7-point scale ranging from 0 ("Not at all") to 6 ("All of the time"). Item scores (0 to 6) are summed to provide a total score range of 0 to 90; higher scores indicate greater impairment of quality of life (QoL). Negative changes from baseline indicate improvement.
Time frame: Baseline, Week 24
| Milestone | Placebo Period 1 | Placebo Period 1, Then Upa 11 mg Period 2 | Placebo Period 1, Then Upa 22 mg Period 2 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 |
|---|---|---|---|---|---|---|
| Started | 46 | 0 | 0 | 49 | 47 | 43 |
| Completed | 44 | 0 | 0 | 46 | 45 | 38 |
| Not completed | 2 | 0 | 0 | 3 | 2 | 5 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 1 | 1 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Placebo Period 1 | Placebo Period 1, Then Upa 11 mg Period 2 | Placebo Period 1, Then Upa 22 mg Period 2 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 |
|---|---|---|---|---|---|---|
| Started | 0 | 21 | 22 | 45 | 45 | 33 |
| Completed | 0 | 19 | 21 | 39 | 38 | 30 |
| Not completed | 0 | 2 | 1 | 6 | 7 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 2 | 6 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 4 | 1 | 1 |
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3, with higher scores indicating more severe disease. Negative changes from baseline indicate improvement.
| Percent change from baseline | Placebo Period 1 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 |
|---|---|---|---|---|
| Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 | -14.36 (-24.86 to -3.85) | -21.96 (-32.18 to -11.75) | -35.63 (-46.11 to -25.14) | -33.96 (-45.41 to -22.50) |
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3, with higher scores indicating more severe disease.
| percentage of participants | Placebo Period 1 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 |
|---|---|---|---|---|
| Percentage of Participants Achieving F-VASI 75 (≥ 75% Improvement in F-VASI From Baseline) at Week 24 | 2.2 (0.0 to 6.4) | 8.2 (0.5 to 15.8) | 19.1 (7.9 to 30.4) | 14.0 (3.6 to 24.3) |
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3, with higher scores indicating more severe disease.
| percentage of participants | Placebo Period 1 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 |
|---|---|---|---|---|
| Percentage of Participants Achieving F-VASI 50 (≥ 50% Improvement in F-VASI From Baseline) at Week 24 | 10.9 (1.9 to 19.9) | 16.3 (6.0 to 26.7) | 38.3 (24.4 to 52.2) | 39.5 (24.9 to 54.1) |
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100, with higher scores indicating more severe disease.
| percentage of participants | Placebo Period 1 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 |
|---|---|---|---|---|
| Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 (≥ 50% Improvement in T-VASI From Baseline) at Week 24 | 2.2 (0.0 to 6.4) | 6.1 (0.0 to 12.8) | 6.4 (0.0 to 13.4) | 11.6 (2.0 to 21.2) |
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100, with higher scores indicating more severe disease. Negative changes from baseline indicate improvement.
| Percent change from baseline | Placebo Period 1 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 |
|---|---|---|---|---|
| Percent Change From Baseline in T-VASI at Week 24 | -6.42 (-13.17 to 0.34) | -13.87 (-20.45 to -7.29) | -17.26 (-24.00 to -10.52) | -20.69 (-28.05 to -13.32) |
The VitiQoL is a validated questionnaire used in clinical trials to assess stigma-related vitiligo impacts. The VitiQoL uses subject-elicited social, affective, and behavior items, asking the subject's appraisal of the vitiligo-related impacts over the last month. Fifteen items are scored on a 7-point scale ranging from 0 ("Not at all") to 6 ("All of the time"). Item scores (0 to 6) are summed to provide a total score range of 0 to 90; higher scores indicate greater impairment of quality of life (QoL). Negative changes from baseline indicate improvement.
| units on a scale | Placebo Period 1 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 |
|---|---|---|---|---|
| Change From Baseline in the Vitiligo Quality-of-Life (VitiQoL) Instrument Total Score at Week 24 | -5.5 (-10.3 to -0.8) | -7.5 (-12.0 to -3.0) | -3.7 (-8.2 to 0.9) | -6.6 (-11.6 to -1.6) |
Collected over All-cause mortality/adverse events were collected from informed consent through the end of the study. Median time on follow-up was 168 days for all groups in Period 1. Median time on follow-up for Period 2 was as follows: Placebo Period 1, Then Upa 11 mg Period 2 (198 days); Placebo Period 1, Then Upa 22 mg Period 2 and Upa 22 mg Period 1, Then Upa 22 mg Period 2 (212 days); Upa 6 mg Period 1, Then Upa 6 mg Period 2 (204 days); and Upa 11 mg Period 1, Then Upa 11 mg Period 2 (207 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Period 1 | 0/46 (0%) | 1/46 (2.2%) | 26/46 (56.5%) |
| Upa 6 mg Period 1 | 0/49 (0%) | 1/49 (2%) | 19/49 (38.8%) |
| Upa 11 mg Period 1 | 0/47 (0%) | 0/47 (0%) | 28/47 (59.6%) |
| Upa 22 mg Period 1 | 1/43 (2.3%) | 3/43 (7%) | 23/43 (53.5%) |
| Placebo Period 1, Then Upa 11 mg Period 2 | 0/21 (0%) | 1/21 (4.8%) | 9/21 (42.9%) |
| Placebo Period 1, Then Upa 22 mg Period 2 | 0/22 (0%) | 0/22 (0%) | 11/22 (50%) |
| Upa 6 mg Period 1, Then Upa 6 mg Period 2 | 0/45 (0%) | 0/45 (0%) | 12/45 (26.7%) |
| Upa 11 mg Period 1, Then Upa 11 mg Period 2 | 0/45 (0%) | 2/45 (4.4%) | 22/45 (48.9%) |
| Upa 22 mg Period 1, Then Upa 22 mg Period 2 | 0/33 (0%) | 0/33 (0%) | 17/33 (51.5%) |
| Event | Placebo Period 1 | Upa 6 mg Period 1 | Upa 11 mg Period 1 | Upa 22 mg Period 1 | Placebo Period 1, Then Upa 11 mg Period 2 | Placebo Period 1, Then Upa 22 mg Period 2 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 |
|---|---|---|---|---|---|---|---|---|---|
| CLAVICLE FRACTUREInjury, poisoning and procedural complications | 0/46 | 0/49 | 0/47 | 0/43 | 1/21 | 0/22 | 0/45 | 0/45 | 0/33 |
| DEATHGeneral disorders | 0/46 | 0/49 | 0/47 | 1/43 | 0/21 | 0/22 | 0/45 | 0/45 | 0/33 |
| PAINGeneral disorders | 0/46 | 0/49 | 0/47 | 1/43 | 0/21 | 0/22 | 0/45 | 0/45 | 0/33 |
| COVID-19 PNEUMONIAInfections and infestations | 0/46 | 0/49 | 0/47 | 1/43 | 0/21 | 0/22 | 0/45 | 0/45 | 0/33 |
| INVASIVE LOBULAR BREAST CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/46 | 0/49 | 0/47 | 0/43 | 0/21 | 0/22 | 0/45 | 1/45 | 0/33 |
| ISCHAEMIC STROKENervous system disorders | 0/46 | 0/49 | 0/47 | 0/43 | 0/21 | 0/22 | 0/45 | 1/45 | 0/33 |
| NEPHROLITHIASISRenal and urinary disorders | 1/46 | 0/49 | 0/47 | 0/43 | 0/21 | 0/22 | 0/45 | 0/45 | 0/33 |
| ARTERIOSCLEROSIS CORONARY ARTERYCardiac disorders | 0/46 | 1/49 | 0/47 | 0/43 | 0/21 | 0/22 | 0/45 | 0/45 | 0/33 |
| Event | Placebo Period 1 | Upa 6 mg Period 1 | Upa 11 mg Period 1 | Upa 22 mg Period 1 | Placebo Period 1, Then Upa 11 mg Period 2 | Placebo Period 1, Then Upa 22 mg Period 2 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 |
|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 8/46 | 7/49 | 9/47 | 9/43 | 1/21 | 5/22 | 7/45 | 12/45 | 5/33 |
| HEADACHENervous system disorders | 4/46 | 0/49 | 9/47 | 2/43 | 2/21 | 1/22 | 2/45 | 5/45 | 2/33 |
| NASOPHARYNGITISInfections and infestations | 3/46 | 4/49 | 2/47 | 4/43 | 3/21 | 3/22 | 1/45 | 2/45 | 2/33 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/46 | 3/49 | 2/47 | 0/43 | 3/21 | 0/22 | 1/45 | 4/45 | 3/33 |
| ACNESkin and subcutaneous tissue disorders | 1/46 | 3/49 | 4/47 | 6/43 | 1/21 | 2/22 | 1/45 | 2/45 | 3/33 |
| URINARY TRACT INFECTIONInfections and infestations | 3/46 | 1/49 | 4/47 | 2/43 | 0/21 | 3/22 | 2/45 | 1/45 | 0/33 |
| FATIGUEGeneral disorders | 1/46 | 2/49 | 2/47 | 5/43 | 1/21 | 0/22 | 2/45 | 0/45 | 0/33 |
| SKIN LACERATIONInjury, poisoning and procedural complications | 0/46 | 0/49 | 0/47 | 0/43 | 2/21 | 0/22 | 0/45 | 0/45 | 0/33 |
| NAUSEAGastrointestinal disorders | 3/46 | 0/49 | 2/47 | 4/43 | 0/21 | 0/22 | 0/45 | 1/45 | 0/33 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 4/46 | 0/49 | 0/47 | 0/43 | 0/21 | 0/22 | 0/45 | 0/45 | 0/33 |
ITT Population in Period 1 (ITT_1): all randomized participants in Period 1, analyzed according to the treatment groups that they were randomized to.
| Age, Continuous(years) | Placebo Period 1 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 | Total |
|---|---|---|---|---|---|
| Mean | 46.8 ± 10.48 | 45.1 ± 11.68 | 45.5 ± 11.90 | 48.2 ± 11.13 | 46.3 ± 11.30 |
| Sex: Female, Male(Participants) | Placebo Period 1 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 | Total |
|---|---|---|---|---|---|
| Female | 29 | 26 | 34 | 26 | 115 |
| Male | 17 | 23 | 13 | 17 | 70 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Period 1 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 6 | 4 | 5 | 20 |
| Not Hispanic or Latino | 41 | 43 | 43 | 38 | 165 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Period 1 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 6 | 6 | 7 | 6 | 25 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 4 | 3 | 3 | 1 | 11 |
| White | 34 | 35 | 36 | 33 | 138 |
| More than one race | 0 | 3 | 1 | 1 | 5 |
| Unknown or Not Reported | 2 | 1 | 0 | 1 | 4 |
| Total Vitiligo Area Scoring Index (T-VASI)(units on a scale) | Placebo Period 1 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 | Total |
|---|---|---|---|---|---|
| Mean | 21.014 ± 16.9516 | 20.993 ± 15.9672 | 22.322 ± 18.1784 | 21.843 ± 15.9324 | 21.534 ± 16.6634 |
| Facial Vitiligo Area Scoring Index (F-VASI)(units on a scale) | Placebo Period 1 | Upa 6 mg Period 1, Then Upa 6 mg Period 2 | Upa 11 mg Period 1, Then Upa 11 mg Period 2 | Upa 22 mg Period 1, Then Upa 22 mg Period 2 | Total |
|---|---|---|---|---|---|
| Mean | 1.043 ± 0.6094 | 1.154 ± 0.7655 | 1.021 ± 0.5781 | 1.159 ± 0.6585 | 1.094 ± 0.6559 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jun 2021 to primary completion in Jan 2023, 18 months.
Results were first posted in Oct 2024, 1 year 8 months after primary completion. A results delay was requested in Dec 2023.
Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's 18 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib